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Background: Few reports can be found in the literature with respect to the impact of neoadjuvant hormonal
therapy (NHT) on operative parameters on laparoscopic radical prostatectomy (LRP) in a large study. The aim of this
study was to evaluate the safety and efficacy of NHT prior to LRP for locally confined prostate cancer.
Methods: From January 2004 to September 2009, 342 patients undergoing LRP were analyzed, specifically
comparing 72 patients who received NHT to 270 who did not. All patients were in clinical stage T2 and nerve
sparing LRP were not included.
Results: The mean patient age, preoperative prostate specific antigen (PSA), clinical stage, and biopsy Gleason
grade were similar for the NHT and the non-NHT LRP groups. The median blood loss and the median operative
time were also similar. There were no differences in the intraoperative complication rate of rectum injury,
blood transfusion, and open surgery conversion. The positive surgical margin rate was significantly improved
in NHT patients. Moreover, PSA recurrence within two years was significantly less in long-term NHT than in
non-NHT patients.
Conclusions: LRP was shown as a safe and efficacious procedure in patients who have received NHT. Perioperative
morbidity of NHT patients undergoing LRP appears equivalent to non-NHT patients, with lower positive surgical
margin, and PSA recurrence rate.
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In recent years, significant improvements have been
made in the early detection of prostate cancer (PCA).
Also, a rapid increase in incidence during the past two
decades has been noted [1]. Radical retropubic prosta-
tectomy (RP), in particular, provides excellent long-term
disease control for patients with clinically localized PCA
[2]. Laparoscopic prostatectomy (LRP), first described by
Schuessler et al. [3], is a standard treatment modality for
localized PCA that seeks to combine the benefits of a
minimally invasive approach with the advantages of sur-
gical removal and pathologic staging of the tumor. This
technique was initiated in our practice in 2001, and
since then more than 500 cases have been experienced.* Correspondence: n-kawai@med.nagoya-cu.ac.jp
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reproduction in any medium, provided the orThe use of neoadjuvant hormonal therapy (NHT) lacks
widespread acceptance in the treatment of PCA patients.
Studies have demonstrated a decrease in pathologic
stage without improvement in prostate specific antigen
(PSA) for disease-free survival in patients receiving
3 months of NHT [3-5]. In contrast, recent studies [6,7]
have shown the effectiveness of NHT was enhanced by
using it for a longer duration (>8 months) or combining
it with androgen blockade. Prostatic apoptosis associated
with prostatic and periprostatic fibrosis has been seen
after NHT. A consensus has not been possible on
whether or not these periprostatic changes make RP
more difficult because of insufficient data on this ques-
tion. To our knowledge, few reports can be found in the
literature with respect to the impact of NHT on opera-
tive parameters on LRP in a large study. However, one
study [8] reported a decrease in seminal vesicle invasion
rate with NHT. Therefore, the aim of this retrospectived. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical characteristics of laparoscopic radical
prostatectomy cases treated with or without neoadjuvant
hormonal therapy groups *p < 0.05
Variables LRP* alone LRP with NHT**
No. of patients 270 72
Mean age ± SD 66.3 ± 6.1 67.7 ± 5.4
Mean serum PSA ± SD, ng/mL 8.64 ± 5.2 9.81 ± 4.1
Biopsy Gleason grade, n(%)
≤ 3 + 3 121 (44.8) 30 (41.7)
3 + 4, 4 + 3 85 (31.5) 25 (34.7)
≥ 4 + 4 64 (23.7) 17 (23.6)
Clinical stage, n(%)
cT1c 100 (37.0) 27 (37.5)
cT2 170 (63.0) 45 (62.5)
D’Amico risk classification, n(%)
low 76 (28.1) 14 (19.4)
intermediate 74 (27.4) 24 (33.3)
high 120 (44.4) 34 (47.2)
Pathological stage, n(%)
pT2 193 (71.5) 62 (86.1)
pT3 77 (28.5) *10 (13.9)
Median operative time, min 260 (121–572) 276 (151–454)
Median blood loss, ml 600 (50–4500) 600 (90–3928)
Intraoperative complication
Rectum injury, n(%) 4 (1.48) 2 (2.78)
Blood transfusion, n(%) 4 (1.48) 2 (2.78)
Open surgery conversion, n(%) 10 (3.70) 3 (4.17)
Positive surgical margin, n(%) 114 (42.2) *20 (27.8)
Biochemical recurrence, n(%) 48 (17.8) 14 (19.4)
Patient characteristics and outcomes in laparoscopic prostatectomy (LRP) only
and LRP with neoadjuvant hormone therapy (NHT) *p < 0.05.
LRP*: laparoscopic radical prostatectomy NHT**: neoadjuvant hormonal
therapy.
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did and did not receive NHT prior to LRP especially in
high risk PCA patients.
Methods
Study population
Between January 2004 and September 2009, 342 men
were scheduled for LRP as the treatment for apparently
localized PCA. LRP was performed as described by
Guillonneau and Vallancien [9]. After removing the
prostate, the specimen was fixed in 10% buffered formal-
dehyde. After removal of the apex and the bladder neck
resection margins, the prostate was sectioned axially at
regular intervals of 5 mm or less, yielding serial slices of
tissue. On each slide, a pathologist outlined the region of
cancer and assigned a Gleason grade. Clinical character-
istics are listed in Table 1. Of the 342 patients, 72 had
received NHT. In the NHT group 50 patients were trea-
ted with anti-androgen and luteinizing hormone-releasing
hormone analogue. The other 22 patients were treated
only with anti-androgen alone. The period of NHT was
3.8 (0.5-24) months prior to LRP. NHT was initiated due
to the concerns of the patients to delay the tumor pro-
gression while waiting for the operation to be scheduled.
Nerve sparing cases were omitted. Preoperative and peri-
operative clinical and pathological data were recorded in-
cluding patient age, preoperative PSA, biopsy Gleason
grade, clinical stage, pathologic stage, blood loss including
urine, intraoperative complications and surgical margin
status. There were no significant differences among the
two groups in clinical characteristics. The oncologic re-
sults were evaluated by staging of the operative specimen
according to the TNM 2002 classification and the last
serum PSA level after operation. PSA recurrence was de-
fined as two consecutive increases > 0.2 ng/mL. The me-
dian follow-up for biochemical recurrence free patients
was 4.5 (2.0-7.5) years. This study was approved by the
institutional review board at Nagoya City University
Hospital and conducted in accordance with Declaration
of Helsinki. Surgical complications were monitored ac-
cording to the Clavien-Dindo Classification. Numerical
parameters between the two groups were compared using
the Student’s t test or Man-Whitney U test when appro-
priate. A P value less than 0.05 was considered significant.Results
Patient characteristics
The clinical features of the patients are shown in Table 1
as indicated previously. Mean patient age ± standard de-
viation (SD) was 66.3 ± 6.1, and 67.7 ± 5.4 for the LRP
alone group and LRP with NHT groups respectively.
Mean serum levels of PSA before prostate biopsy and
prostate biopsy Gleason scores were similar in the twogroups. About 37% of each group was in clinical stage
cT1c. The two groups were equally balanced for clinical
characteristics.
Influence on operation and postoperative parameters
There were no differences in median operative times
(260 min in LRP alone, and 276 min in LRP with NHT),
and in median blood loss (600 ml in LRP alone, and
600 ml in LRP with NHT). With respect to the intrao-
perative complications, no differences were seen in the
rate of rectum injury, open surgery conversion, and the
necessity of blood transfusion. All complications were
less than grade 1 in the Clavien–Dindo Classification,
and were treated as routine procedures. There was also
no difference in the complication rate between the two
groups on the history of abdominal surgery. Several
patients had experienced an appendectomy or total
Table 2 Comparison of neoadjuvant hormonal
therapy period treated with laparoscopic radical
prostatectomy patients
Variables Group A* Group B**
No. of patients 47 25
Mean age ± SD 67.4 ± 5.6 68.3 ± 4.7
Preoperative serum PSA ± SD, ng/mL 10.0 ± 3.9 9.38 ± 4.4
Biopsy Gleason grade, n(%)
≤ 3 + 3 20 (42.6) 10 (40.0)
3 + 4, 4 + 3 20 (42.6) 5 (20.0)
≥ 4 + 4 7 (14.9) 10 (40.0)
D’Amico risk classification, n(%)
low 11 (23.4) 3 (12.0)
intermediate 17 (36.2) 7 (28.0)
high 19 (40.4) 15 (60.0)
Kind of neoadjuvant hormonal therapy
CAB 32 (68.1) 18 (72.0)
anti-androgen alone 15 (31.9) 7 (28.0)
Pathological stage, n(%)
pT2 42 (89.4) 20 (80.0)
pT3a 3 (6.40) 4 (16.0)
pT3b 2 (4.30) 1 (4.00)
Median operative time, min 286 (151–454) 270 (152–410)
Median blood loss, ml 600 (90–3928) 552 (95–1600)
Positive surgical margin, n(%) 13 (27.7) 7 (28.0)
Biochemical recurrence, n(%) 13 (27.7) *1 (4.00)
Patient characteristics and outcomes in two NHT patient groups (Group A: NHT
on LRP for less than 3 months, Group B: NHT on LRP for more than 3 months)
*p < 0.05.
Group A*: laparoscopic radical prostatectomy cases treated with neoadjuvant
hormonal therapy for less than 3 months.
Group B**: laparoscopic radical prostatectomy cases treated with neoadjuvant
hormonal therapy for more than 3 months.
CAB: combined androgen blockade with anti-androgen and LHRH analogue.
*p < 0.05.
CAB: combined androgen blockade with anti-androgen and LHRH analogue.
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in such patients (data not shown). There was no mortal-
ity in this series. Positive surgical margin (PSM) was
demonstrated in 114 (42.2%) in the LRP alone group
and in 20 (27.8%) in LRP with NHT group. The differ-
ence between these two groups was significant. The apex
was the most common location of PSM in each group
(data not shown).
Influence on biochemical recurrence free survival rate
The PSM rate was significantly lower in patients that
were treated with NHT. In all, 62 patients had biochem-
ical recurrence (BCR) (48 in LRP alone and 14 in LRP
with NHT). The 2-year BCR free probability was similar
between the two groups. For further analysis of pro-
longed NHT, the LRP with NHT group was divided into
two groups of less than 3 months (Group A) and more
than 3 months (Group B). The clinical features of the
patients are shown in Table 2. No clinical differences
emerged from studies of the two groups. The compari-
sons of median blood loss and operative time, and the
rate of rectum injury, open surgery conversion, and ne-
cessity of transfusion were all not significant. In this ana-
lysis, the PSM rate was similar between the two groups,
but the 2-year BCR rate was significantly lower in group
B than in group A: (13 patients (27.7%) in Group A, ver-
sus one patient (4.00%) in Group B).
Discussion
There is no consensus in the medical literature as to
whether RP after NHT is of greater, equal, or of lesser
difficulty than RP in patients who have not received
NHT. Some have stated that NHT decreases the opera-
tive parameters and thereby facilitates the surgical pro-
cedure [10,11]. Others have reported no differences in
operative time, blood loss, transfusion rate, or complica-
tion rate in patients who received or did not receive
NHT prior to RP [12-14]. Our interest was directed at
learning if the inability to palpate the prostate in these
cases would make LRP more difficult, especially in the
first group of cases that were encountered. In order to
focus on this problem, a retrospective study was per-
formed on our large number of patient outcomes. Both
patient groups who did and did not receive NHT showed
similarities in preoperative clinical features, operative
times, blood loss, and intraoperative complication rates.
Thus, it appears that LRP is a safe procedure that can be
performed easily in both groups of patients.
In this series, the effect of prolonged NHT (over
4 months) was compared to less than 3 months NHT,
and no impact was found on operative parameters.
Gleave et al. [4] reported a mean blood loss of 761 ml
and no major intraoperative morbidity after 8 months of
NHT. After 4 months of NHT, Powell et al. [15] foundRP was feasible in terms of resectability in patients who
earlier might have been considered inoperable due to
clinical stage T3/T4 disease. As to LRP, Rassweiler et al.
[16] evaluated 180 patients who underwent LRP. Of
these, NHT was given in 42 patients (23.3%) that
required a longer operative time (321 min) and higher
blood transfusion rate (46%) than in patients without
NHT. However, in our study, the operative parameters
between prolonged NHT and short term NHT were
similar. This might be partly due to the recent advances
of surgical instruments, for example, clear view system,
or superior blood coagulation devices. Nowadays, robot-
assisted laparoscopic radical prostatectomy (RALP) is
gaining in popularity for the treatment of clinically loca-
lized PCA. The benefits of RALP are minimally invasive
surgery with wide and 3-dimensional vision and delicate
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sonable and safe, and constitute an effective treatment
modality superior to not only RP but also LRP. There-
fore, RALP after NHT might be a feasible option in loca-
lized PCA patients.
The BCR free survival is another focus of attention
after NHT prior to RP. Meyer et al. [5] reviewed 680
men and follow-up for 38 months after RP. They
reported a 33% PSA recurrence rate. The literature is in-
adequate on the impact of NHT on the outcome of LRP.
As to LRP, Pu et al. [6] evaluated 55 patients with clinic-
ally localized PCA who were treated with NHT for 3-
months (25 patients), and for 8-months (19 patients)
and those with non-NHT (11 patients) before LRP. The
PSM rate was significantly lower in the 3- or 8-months
NHT groups than in the non-adjuvant group (P < 0.05,
respectively). Also, there was no difference between the
3- and 8-months groups with respect to PSM rate. How-
ever, they had no follow-up data as to whether or not
prolonged (8-months) NHT prior to LRP altered BCR
rates. Table 3 reviews the impact of NHT prior to LRP
on PSM and BCR rate [6,7,16-18]. Brown et al. [7] stud-
ied the safety and efficacy of LRP after NHT. LRP
appeared to be a safe and efficacious procedure. These
results were based on 5 patients who received NHTTable 3 Comparison of neoadjuvant hormonal therapy on the
References Period of NHT* (months) No. of patients Tra
Rassweiler et al. [14]
NHT group NA 42
non-NHT group - 138
Gregori et al. [15]
NHT group less than 3 21
non-NHT group - 59
Brown et al. [7]
NHT group less than 3 5
non-NHT group - 60
Maldonado-Valadez et al. [16]
NHT group 3.5 50
non-NHT group - 50
Pu et al. [6]
NHT group 3 25
8 19
non-NHT group - 11
Our series
NHT group 3 or less 47
more than 3 25
non-NHT group - 270
Reviews of the impact of NHT prior to LRP on operative and postoperative paramet
NHT*: neoadjuvant hormonal therapy PSM**: positive surgical margin BCR***: bioch
NA: not available PSM: positive surgical margin BCR: biochemical recurrence.against 60 who did not. They also noted that 2 of 60
patients in the non-NHT group had biochemical recur-
rence, compared to 0 of 5 patients in the NHT group.
This data of a small number of patients and short study
term discouraged any statistical study of the cohorts. In
contrast, our data includes an extended median follow-
up period of 4 years, which strengthens the case for
NHT improving BCR free survival. Further large scale
prospective investigations are needed.
Several limitations and factors might account for the
lack of difference in BCR rates despite improved PSM
rates between the non-NHT and NHT groups. In the
present study about 25% were low risk patients accord-
ing to the D’Amico classification (PSA < 10 ng/mL, bi-
opsy Gleason score < 7, cT1) with an associated low risk
of BCR after RP alone. Such patients might derive little
benefit from the addition of NHT. Similar to other pre-
vious studies, this trial was also initially designed to
identify differences in pathological stage and not pow-
ered to detect differences in BCR. NHT causes shrinkage
and condensation of the benign prostate tissue around
the tumor. Thus, while the apoptosis caused by NHT
may increase the number of apparently negative mar-
gins, tumors may actually be closer to the prostate cap-
sule, margin, and seminal vesicle. The lack of aoutcome of laparoscopic radical prostatectomy
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follow-up might be due to insufficient sample size. In a
meta-analysis that combined several studies to include
1129 men, NHT did not improve BCR rates after RP. In
another study of 156 patients treated with 8 months of
NHT, Gleave et al. [19] reported low PSM (12%) and
BCR (12.2%) rates at a mean follow up of 54 months. In
our study, there was no difference in preoperative risk
between the two groups (LRP alone vs. LRP with NHT)
in Table 1. However, the number of pathological stage
T3 patients was significantly lower in the NHT group.
Table 2 shows the high risk PCA patients tended to be
higher in the long-term NHT group, but the BCR rate
was significantly lower. Although this was a retrospect-
ive study, a longer NHT period might decrease the ac-
tive capsular penetration and seminal vesicle invasion,
and as a result prevent the biochemical recurrence. Our
findings suggest that the optimal duration of NHT on
LRP might be over 3 months similar to RP.
In Japan, there are a limited number of large institutes
where LRP can be performed. A Japanese preoperative
nomogram was reported which indicated the probability
of extracapsular penetration after surgery is 15-27% in
low risk patients [20]. Patients were informed of the
probability and the risk of comorbidity before surgery.
When the patient chose the NHT, it was performed
according to the waiting time for the operation. There
was no comorbidity in long-term NHT group. To truly
assess the appropriateness of NHT requires a careful
consideration of the growing evidence of risk of the car-
diac and metabolic diseases associated with such long-
term exposure to androgen deprivation. Consequently,
many diagnosed cases of PCA have a long waiting period
before surgery can be scheduled. Thus, many cases are
treated with NHT to suppress the progression of the
malignancy. Our data showed that LRP is safe and ef-
fective for the treatment of PCA in men who received
NHT. The longer period of NHT can reduce the PSM,
and might improve the BCR free survival on LRP.
Conclusion
LRP was shown as a safe and efficacious procedure in
patients who have received NHT. Perioperative morbid-
ity of NHT patients undergoing LRP appears equivalent
to non-NHT patients, with lower positive surgical mar-
gin, and PSA recurrence rate.
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